Pharmaceutical Technology Editors

In addition to globalisation, high financial rewards and low penalties for counterfeiters are contributing to the rise in fake medicines.

Nathan Jessop reviews the pharmaceutical industry's experience with the first year of Germany?s new pricing policy.

A few years ago, drug criminals would put all their efforts into matching packaging and labeling, or manufacturing good-looking fake materials. Today, criminals are capable of much more.

The EMA brought together European and US expert representatives from regulatory authorities, academia, industry and a health-technology-assessment agency on Nov. 18, 2011 to discuss the use and importance of subgroup analysis in the assessment of clinical trials.

Takeda Forms New Global Medical Affairs Department; UCB, NewBridge Pharmaceuticals Partner for Middle East and African Markets; and More.

EMA addresses drug supply shortage.

German Court Finds AstraZeneca's Seroquel XR Formulation Patent Invalid; FDA Advisory Committee to Recommend Approval of GSK's H5N1 Influenza Vaccine Candidate; and More.

USP announces new drug naming policy and FDA releases two guidance documents.

Neptune Provides Update on Incident at its Production Plant; Tekmira and Alnylam Restructure Relationship and Settle All Litigation; and More.

FDA provides information on its Enhanced Communication Team created in response to PDUFA V.

Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More.

A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

FDA pushes back goals due to Hurricane Sandy and EMA announces changes to variation regulations.

Novartis to Construct New Biotechnology Facility in Singapore; Patheon to Acquire Banner Pharmacaps; and More.

Pfizer Announces Intention to Acquire NextWave Pharmaceuticals; Seattle Genetics Expands ADC Collaboration with Abbott; and More.

FDA announces Coalition for Accelerating Standards and Therapies and Commissioner Hamburg comments on meningitis outbreak.

Catalent Licenses NJIT Taste-Masking Technology; MicroConstants Completes FDA Inspection; and More.

EMA releases guideline on medicinal products for the treatment of schizophrenia.

Mayne Pharma to Acquire Metrics; Sanofi, Bristol-Myers Squibb Restructure Plavix Alliance; and More.

Merck Returns Brinavess Rights to Cardiome; Sigma-Aldrich Expands in Scotland; and More.

FDA launches BeSafeRx program and releases guidance for industry.

Mallinckrodt Agrees to Acquire CNS Therapeutics; Sanofi Outlines R&D Restructuring; and More.

Although CPhI, ICSE, InnoPak and and P-Mec won’t begin until 9 October, you can start your CPhI experience a dary earlier on 8 October by attending the preshow Pre-Connect Conference.

Pfizer Launches Joint Venture In China; Spectrum Sartorius Opens New Facility In Germany; And More.

Cambridge Major Laboratories Expands API Manufacturing Facility; Spectrum Completes Acquisition of Allos Therapeutics; and More.

Lilly Stops Phase III Development of Pomaglumetad Methionil; Hospira to Acquire API Manufacturing and R&D Facilities; and More.

USP Hosts Symposium on Science and Standards

A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

The Johnson & Johnson subsidiary Janssen Pharmaceuticals has announced a settlement and consent decree with 36 states and the District of Columbia in regards to previously disclosed allegations related to the company's marketing and promotional practices relating to Risperdal (risperidone).

AstraZeneca Names Pascal Soriot CEO; The Merck Group Agrees to Acquire Biochrom; and More.